Previous 10 |
Aimmune Therapeutics (NASDAQ: AIMT ): Q4 GAAP EPS of -$0.95 misses by $0.04 . More news on: Aimmune Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
FDA decision on AR101 BLA filing acceptance expected by end of March Submission of AR101 marketing application in Europe on track for mid-2019 Initiation of AR201 phase 2 trial in egg allergy on track for mid-2019 Company began 2019 with approximately $340 million in cas...
ACHC , ADSK , AGO , AIMT , ALRM , ALTR , AMBC , AMC , APPF , AQN , ATRC , BIO , BLDR , CARG , CISN , CSLT , DCO , DDD , DELL , EDIT , EIX , EQH , FTCH , GCAP , GPS , GSBD , HABT , ICUI , JAG , JWN , KTOS , KWR , LYV , MAIN , MAR , MAXR , MTZ , NKTR , N...
— AR101 Associated with 70% Reduction in Allergic Reactions Due to Accidental Exposures That Required Treatment Compared to Placebo After Dose Escalation in PALISADE — — AR101-Treated Patients Who Completed PALISADE Had 95% Increased Probability of Tolerating Any D...
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss its financial results for the quarter and full-year ...
Aimmune ( AIMT ) suffered a setback and through no fault of its own. It was notified by the FDA that its Biologics Licensing Application ((BLA)) would not be reviewed because of the government shutdown. The stock fell about 5% on Monday after the release of the news, and then slightly ag...
— Nine Abstracts Featured, Including Data on Longer-Term AR101 Efficacy and Safety and PALISADE Accidental Exposures — Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today anno...
News, Short Squeeze, Breakout and More Instantly...
Aimmune Therapeutics Inc. Company Name:
AIMT Stock Symbol:
NASDAQ Market:
Aimmune Therapeutics Inc. Website:
— Majority of Patients Experienced Low Rates of Adverse Events, Which Declined in Frequency and Severity with Continued Treatment — — Systemic Allergic Reactions and Epinephrine Use Were Low and Decreased Over Time — Aimmune Therapeutics, ...
-- Peanut Allergy is One of the Most Common Food Allergies in Europe -- -- Up to 1.6% of European Children Live with Potentially Life-Threatening Peanut Allergy -- Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Com...
VEVEY, Switzerland , Sept. 14, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. ("Purchaser"), is commencing today a cash tender offer to purchase all of the outstanding shares of common s...